Florida Monoclonal Antibody Treatment Sites Closed After FDA Withdraws Emergency Use Authorization

Florida Monoclonal Antibody Treatment Sites Closed After FDA Withdraws Emergency Use Authorization

Florida’s plan to help prevent hospitalizations among those with COVID-19 came to an abrupt end on Monday, after the Food and Drug Administration (FDA) removed the treatment from Emergency Use Authorizations.

In a statement released Monday evening, the Florida Department of Health said in a statement that the decision would mean that monoclonal antibody treatment would be closed until “further notice.”

“This evening, without any advanced notice, the US Food and Drug Administration (FDA) revised the Emergency Use Authorization (EUA)…The revised EUAs do not allow providers to administer these treatments within the United States,” the statement reads.

“Unfortunately, as a result of this abrupt decision made by the federal government, all monoclonal antibody state sites will be closed until further notice…Florida disagrees with the decision that blocks access to any available treatments in the absence of clinical evidence.”

The reason given by the FDA was that the treatment was likely not effective against the omicron variant.

The White House on Tuesday would defend the FDA’s decision during a press conference, with Press Secretary Jen Psaki saying: “We’ve approached COVID treatments like filling a medicine cabinet. We’re not relying on one type, one brand, or treatment. We invested in and continue to buy a variety across monoclonal antibodies, pre-exposure prevention therapies, and oral anti-virals.”

“What the FDA is making clear is that these treatments, the ones that they are fighting over, that the governor is fighting over, do not work against omicron and they have side effects. That is what the scientists are saying,” said Psaki.

“People have a right to access these treatments, and to revoke it on this basis is just fundamentally wrong and we’re going to fight back,” DeSantis said in response to the news.

Critics of the Biden regime were quick to blast the decision on social media:


Join the Newsletter